Phathom Pharmaceuticals (PHAT) Stock Chart & Stock Price History $4.41 +0.19 (+4.50%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$4.40 0.00 (-0.11%) As of 03/14/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Phathom Pharmaceuticals Stock Price Performance 5 Day Performance-7.93%1 Month Performance-23.57%3 Month Performance-45.82%6 Month Performance-76.65%Year-To-Date Performance-45.69%1 Year Performance-48.06% Receive PHAT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Remove Ads PHAT Stock Chart for Sunday, March, 16, 2025 PHAT Chart by TradingViewRemove Ads Phathom Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization03/14/2025$4.22$4.41+4.50%$4.48$4.071.24 million shs$301.54 million03/13/2025$5.00$4.22-15.60%$5.05$4.191.42 million shs$288.55 million03/12/2025$4.79$5.00+4.38%$5.25$4.621.53 million shs$341.89 million03/11/2025$4.40$4.79+8.86%$4.85$4.321.59 million shs$327.53 million03/10/2025$5.06$4.40-13.04%$5.07$4.341.82 million shs$300.86 million03/07/2025$5.90$5.06-14.24%$5.77$5.021.81 million shs$345.99 million03/06/2025$6.08$5.90-2.96%$6.98$5.352.35 million shs$403.42 million03/05/2025$5.58$6.08+8.96%$6.21$5.641.03 million shs$415.73 million03/04/2025$5.21$5.58+7.10%$5.61$5.07863,055 shs$381.54 million03/03/2025$5.52$5.21-5.62%$5.91$5.151.05 million shs$356.24 million Get the Latest News and Ratings for PHAT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 02/28/2025$5.76$5.52-4.17%$5.74$5.36946,894 shs$377.44 million02/27/2025$5.79$5.76-0.52%$5.87$5.62664,357 shs$393.85 million02/26/2025$5.58$5.79+3.76%$6.18$5.671.21 million shs$395.90 million02/25/2025$5.34$5.58+4.49%$5.70$5.31989,587 shs$381.54 million02/24/2025$5.67$5.34-5.82%$5.70$5.311.22 million shs$365.15 million02/21/2025$5.54$5.67+2.35%$5.76$5.53723,043 shs$387.72 million02/20/2025$5.76$5.54-3.82%$5.76$5.50639,106 shs$378.83 million02/19/2025$5.72$5.76+0.70%$5.91$5.58846,340 shs$393.87 million02/18/2025$5.77$5.72-0.87%$6.02$5.521.18 million shs$391.13 million02/17/2025$5.77$5.77$6.21$5.751.24 million shs$394.55 million Related Companies Calliditas Therapeutics AB (publ) Stock Price Chart Structure Therapeutics Stock Price Chart Spyre Therapeutics Stock Price Chart Aurinia Pharmaceuticals Stock Price Chart Syndax Pharmaceuticals Stock Price Chart ARS Pharmaceuticals Stock Price Chart 89bio Stock Price Chart Nurix Therapeutics Stock Price Chart Vir Biotechnology Stock Price Chart Adaptive Biotechnologies Stock Price Chart Receive PHAT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PHAT) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMore important than tariffs for your stocksMost people are obsessed with Trump's on-again, off-again tariffs. Yes, the economic uncertainly is playin...Chaikin Analytics | SponsoredMarch 18th: Gold SHOCK?Starting March 18th, a major shift could send gold soaring — or crashing. Either way this shift goes... ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
